GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cyclically Adjusted PS Ratio

GLPG (Galapagos NV) Cyclically Adjusted PS Ratio : 4.59 (As of May. 28, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Cyclically Adjusted PS Ratio?

As of today (2025-05-28), Galapagos NV's current share price is $28.97. Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $6.31. Galapagos NV's Cyclically Adjusted PS Ratio for today is 4.59.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

GLPG' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.62   Med: 7.12   Max: 35.11
Current: 4.42

During the past years, Galapagos NV's highest Cyclically Adjusted PS Ratio was 35.11. The lowest was 3.62. And the median was 7.12.

GLPG's Cyclically Adjusted PS Ratio is ranked better than
55.31% of 499 companies
in the Biotechnology industry
Industry Median: 5.33 vs GLPG: 4.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Galapagos NV's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.231. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.31 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted PS Ratio Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.06 9.12 7.27 6.67 4.65

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.29 4.18 4.60 4.65 3.98

Competitive Comparison of Galapagos NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PS Ratio falls into.


;
;

Galapagos NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Galapagos NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=28.97/6.31
=4.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Galapagos NV's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.231/134.3475*134.3475
=1.231

Current CPI (Mar. 2025) = 134.3475.

Galapagos NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.387 100.107 0.519
201509 0.164 100.245 0.220
201512 0.201 100.572 0.269
201603 0.248 101.653 0.328
201606 0.671 102.267 0.881
201609 0.264 102.118 0.347
201612 1.815 102.614 2.376
201703 0.786 103.972 1.016
201706 0.603 103.902 0.780
201709 0.640 104.170 0.825
201712 0.915 104.804 1.173
201803 0.915 105.419 1.166
201806 1.119 106.063 1.417
201809 2.089 106.618 2.632
201812 2.019 107.252 2.529
201903 0.683 107.876 0.851
201906 1.208 107.896 1.504
201909 11.654 107.470 14.569
201912 1.810 108.065 2.250
202003 1.538 108.550 1.904
202006 1.725 108.540 2.135
202009 2.292 108.441 2.840
202012 2.906 108.511 3.598
202103 2.028 109.522 2.488
202106 2.570 110.305 3.130
202109 1.152 111.543 1.388
202112 -1.442 114.705 -1.689
202203 2.256 118.620 2.555
202206 2.213 120.948 2.458
202209 2.048 124.120 2.217
202212 -2.953 126.578 -3.134
202303 0.946 126.528 1.004
202306 0.995 125.973 1.061
202309 0.983 127.083 1.039
202312 0.998 128.292 1.045
202403 1.030 130.552 1.060
202406 1.279 130.691 1.315
202409 1.001 130.968 1.027
202412 1.200 132.346 1.218
202503 1.231 134.348 1.231

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (NAS:GLPG) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Galapagos NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.